Prospective, randomised, controlled study on the efficacy and safety of different strategies of tranexamic acid with total blood loss, blood transfusion rate and thrombogenic biomarkers in total knee arthroplasty: study protocol
Open Access
- 26 February 2021
- Vol. 11 (2), e038399
- https://doi.org/10.1136/bmjopen-2020-038399
Abstract
Introduction Total knee arthroplasty (TKA) is a common and highly effective orthopaedic procedure for treating end-stage knee osteoarthritis. Tranexamic acid (TXA) has become a routine part of perioperative care in TKAs. The best practices regarding the delivery method of TXA in TKA remain controversial. Plasminogen activator inhibitor-1 (PAI-1), thrombin–antithrombin (TAT) complexes and prothrombin fragment F1+2 (F1+2) have been demonstrated to be elevated in patients with venous thromboembolism (VTE). The aim of this trial was to investigate the most efficacious delivery method of TXA (comparison of intravenous and topical applications and comparison of three topical applications) and to evaluate the safety of TXA strategies by investigating the effect of TXA on the plasma D-dimer, PAI-1, TAT and F1+2 levels. Methods and design This trial is a prospective, randomised, controlled study that will evaluate the efficacy and safety of strategies of TXA. A total of 250 patients undergoing primary TKA will be randomly allocated to five groups for different TXA applications. The primary outcome is total blood loss. The secondary outcomes are blood transfusion rate, drainage volume, plasma D-dimer, PAI-1, TAT and F1+2 levels, maximum haemoglobin drop, wound complications, VTE and length of hospital stay. Ethics and dissemination This study’s protocol is in accordance with the declaration of Helsinki. The ethics committee of the General Hospital of Ningxia Medical University approved this study (approval ID: 2020–505). The results of this study will be disseminated in international peer reviewed journals. Trial registration number ChiCTR2000030624.Funding Information
- Ningxia University Scientific Research Project (NGY2020050)
- Ningxia key R & D program key project: Basic Research and Clinical Application of Geriatric Orthopedic Diseases (2018BEG02005)
This publication has 33 references indexed in Scilit:
- Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trialArchives of orthopaedic and trauma surgery, 2015
- Blood Transfusion in Primary Total Hip and Knee Arthroplasty. Incidence, Risk Factors, and Thirty-Day Complication RatesJournal of Bone and Joint Surgery, 2014
- Association of perioperative blood transfusion and adverse events after operative treatment of proximal humerus fracturesInjury, 2014
- Topical Application of Tranexamic Acid in Primary Total Hip Arthroplasty: A Randomized Double-Blind Controlled TrialThe Journal of Arthroplasty, 2014
- Transfusion‐related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012Transfusion, 2014
- Comparison of Intravenous versus Topical Tranexamic Acid in Total Knee Arthroplasty: A Prospective Randomized StudyThe Journal of Arthroplasty, 2014
- SPIRIT 2013: new guidance for content of clinical trial protocolsThe Lancet, 2013
- CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trialsInternational Journal of Surgery, 2011
- Projections of Primary and Revision Hip and Knee Arthroplasty in the United States from 2005 to 2030The Journal of Bone & Joint Surgery, 2007
- Plasminogen Activator Inhibitor Type-1 in Cardiovascular Disease: Status Report 2001Thrombosis Research, 2001